Tumors of the Urinary System and Male Genital Organs: 2022 World Health Organization Classification and Multidisciplinarity-Reference-Cited by-同舟云学术

Tumors of the Urinary System and Male Genital Organs: 2022 World Health Organization Classification and Multidisciplinarity

Published:2022-11 Issue:5 Volume:82 Page:483-486
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Montironi Rodolfo,Cimadamore Alessia

Publisher

Elsevier BV

Subject

Urology

Reference15 articles.

1. International Agency for Research on Cancer. WHO classification of tumours: urinary and male genital tumours. ed. 5. Vol. 8. Lyon, France: IARC; 2022.

2. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours;Moch;Eur Urol,2022

3. The 2022 World Health Organization classification of tumors of the urinary system and male genital organs—part B: prostate and urinary tract tumors;Netto;Eur Urol,2022

4. Pathology and genetics: tumours of the urinary system and male genital system: clinical implications of the 4th edition of the WHO classification and beyond;Montironi;Eur Urol,2016

5. Tumours of the kidney;Eble,2004

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies;Cell Death & Disease;2024-06-19

2. Progress and application of intelligent nanomedicine in urinary system tumors;Journal of Pharmaceutical Analysis;2024-03

3. Long noncoding RNA GPRC5D-AS1 in renal cell carcinoma: a molecular mechanism study;Translational Andrology and Urology;2024-02

4. The mechanism and clinical application of DNA damage repair inhibitors combined with immune checkpoint inhibitors in the treatment of urologic cancer;Frontiers in Cell and Developmental Biology;2023-05-25

5. Update on combined immunotherapy for the treatment of advanced renal cell carcinoma;Human Vaccines & Immunotherapeutics;2023-01-02